We studied the survival of 195 patients with agnogenic myeloid metaplasia (AMM) diagnosed between 1962 and 1992 in an attempt to stratify patients into risk groups. Median survival was 42 months. Adverse prognostic factors for survival were age > 60 years, hepatomegaly, weight loss, low hemoglobin level (Hb), low or very high leukocyte count (WBC), high percentage of circulating blasts, male sex, and low platelet count. A new scoring system based on two adverse prognostic factors, namely Hb e 10 g/dL and WBC e 4 or >30 x l@/L, was able to separate patients in three groups with low (0 factor), intermediate (1 factor), and high (2 factors) risks, associated with a median survival of 93, GNOGENIC MYELOID metaplasia (AMM) is a mye-A loproliferative disorder characterized by bone marrow Address reprint requests to Brigitte Dupriez, MD, Service d'Hdmtologie Clinique, Centre Hospitalier Dr Schafier,
(BM) fibrosis and extramedullary hematopoiesis. Individual clinical course ranging from 1 to over 30 years has been reported, with a median survival of approximately 4 years from diagnosis.'-' Progressive marrow failure, transformation into acute nonlymphoblastic leukemia (ANLL), and portal hypertension (PHT) are the major causes of death. Several clinical and biological prognostic parameters have been studied, with varying and sometimes conflicting results, except for anemia, constantly associated with short survival.'-7 In addition, we previously reported the adverse prognostic value of abnormal karyotype. 6 In this study on 195 AMM patients, we report a prognostic analysis of survival and progression to ANLL and PHT. Using multivariate analysis, we develop a new simple scoring system for clinical use and confirm the independent prognostic value of cytogenetics.
MATERIALS AND METHODS

Patients.
Between January 1962 and December 1992, we diagnosed AMM in 195 patients. All patients fulfilled the polycythemia vera study group criteria for AMM, which were splenomegaly, red cell poikilocytosis, leukoerythroblastosis, absence of monocytosis, BM fibrosis without any identifiable cause, and absence of Philadelphia chromosome.' Patients with postpolycythemia myelofibrosis (MF), acute (malignant) MF, and myelodysplastic syndromes with MF were excluded? Hematologic examinations were performed by standard methods: peripheral blood (PB) and BM May-Griinwald-Giemsa stained films. BM trephine biopsy was performed at diagnosis in all patients and stained with standard and silver stain for reticulin fibers; three stages of MF were defined according to the usual classification."
Cytogenetic analysis was available at diagnosis in 94 of 133 patients diagnosed since 1980 (48.2% of the whole group). Metaphases were obtained on BM or blood samples, after short-term (24 hours) culture without stimulation. Chromosomes were analyzed with conventional Giemsa stain and the R banding technique and classified according to the Intemational System for Cytogenetic Nomenclature." Any anomaly present in at least three cells was considered clonal.
Treatment was based on age, presence of a poor performance status, importance of cytopenias, or myeloproliferative features. More precisely, 34 asymptomatic patients received no treatment and 52 received supportive care only (essentially transfusion). One hundred nine patients received at least one of the following therapies: 82 patients with very large or symptomatic splenomegaly and very high white cell or platelet counts received one or more
Treatment.
26, and 13 months, respectively. An abnormal karyotype (32 cases of 94 tested patients) was associated with a short survival, especially in the low-risk group (median survival of 50 v 112 months in patients with normal karyotype). The prognostic factors for acute conversion were WBC > 30 x 10s/L and abnormal karyotype. Thus, hemoglobin level and leukocyte count provide a simple prognostic model for survival in AMM, and the adverse prognostic value of abnormal karyotype may be related to a higher rate of acute conversion. All analyses were performed with the statistical application system (SAS) software (SAS Institute Inc, Cary, NC). The closing date was June 1, 1994. The survival curves were drawn by the Kaplan-Meier product limit method." Survival was measured from diagnosis to death or last follow-up. Progression to ANLL was defined by the presence of >30% BM blasts or >20% PB blasts. Statistical comparisons between actuarial survival curves were based on log rank and Cox tests.
The parameters significant at the .05 level for survival were introduced in a first proportional hazards model regression analysis of survival (Cox model) with the forward stepwise ~election. ' two variables were selected for inclusion in a scoring system (named LILLE score). For routine clinical use, we examined a categorized model with the two selected variables and their optimal cutoff values. We validated this model in the test sample and in the overall group of 195 patients with the log-rank test.
Because karyotype was available in only 94 patients, the prognostic value of this variable (normal v abnormal) was assessed separately by univariate analysis, and a last Cox model was built with the following covariates: karyotype and LILLE score.
The prognostic factors for time to death from ANLL or PHT were analyzed by the log-rank test.
RESULTS
There were 105 males and 90 females, with a median age of 65 years (range 27 to 85). Sixty patients (30.8%) were 5 6 0 years old and 18 (9.2%) 5 5 0 years. Anemia was present in 139 cases (71.3%) and Hb < 10 gldL in 44.6%. WBC exceeded 30 X 109/L in 22 cases (11.2%), and 16 patients (8.2%) had leukopenia. Thrombocytopenia was encountered in 5 1 patients (26.2%) and thrombocytosis in 56 (28.7%). All but 7 patients (3.6%) had immature granulocytes, whereas 104 patients (53.3%) had PB blasts with a percentage 2 5% in only 19 cases (9.7%). Thirty-two patients (34%) had clonal chromosomal abnormalities, present either in all cells (19 cases) or coexisting with normal metaphases (13 cases with a mosaicism): de12Oq (11 cases); dell3q (8 cases); trisomy 8 (4 cases); trisomy 21 or add (21) @11) (2 cases); de1(12)(q22) (2 cases); -Y (2 cases); and several others, accounting for one case each del(S)(pl4), -12, -17, -18, dup(l)(q32;q44), der(l7) t(12; 17)(q24;ql l), 12, +19, t(13; 17)(q31;q22), t(1;7) (p31;p22), t(9;21)(p23;qll). Seven subjects exhibited complex aberrations. Patients with abnormal karyotype presented with weight loss more frequently than other patients (P = .02). No other difference in initial characteristics were found.
With a median follow-up of 36 months, the median survival of the 195 patients was 42 months (range 1 to 228). At the time of the analysis, 148 patients (75.9%) had died, 40 were still alive 16+ to 216+ months from diagnosis, and 7 (3.6%) were lost to follow-up. The actuarial survival rates at 2 and 5 years were 68% 5 3% and 40% 2 4%, respectively (Fig 1) . The optimal cutoff value for Hb level was 10 g / a . Both patients with leukopenia or WBC counts > 30 X 109L had identical survival (Fig 2) . Thus, this variable could be categorized into two subgroups, namely high-risk patients with WBC > 30 x 109L or <4 x 10% and low-risk patients with WBC The percentage of immature granulocytes, the BM staging, the spleen size, and the reticulocyte count had no prognostic value for survival at the .01 level. 4 X lo9& and 5 3 0 X 109L. was available in only 94 patients, this variable was removed from the subsequent analysis. The Cox proportional hazards regression method, performed in the overall group of patients with all significant variables except karyotype, selected six parameters: Hb level, WBC count, weight loss, age, sex, and circulating blasts. They are listed in the order entered by the forward stepwise modeling procedure in Table 2 . A similar forward stepwise regression analysis was performed in the training group of 130 patients. Six variables were selected: Hb level, WBC count, weight loss, sex, blasts, and age. Another regression analysis performed with the best selection in the training sample of patients identified an Therapeutic modalities did not influence survival, except for transfusion; survival of patients who required packed red cells was shorter than survival of patients who did not (P = .OOOl). This later correlation was probably related to the adverse prognostic value of anemia.
As expected, the scoring systems of Njoku and Visani had a strong prognostic value for survival (P = However reticulocytes and WBC precursors (taking into account either IG alone or IG + blasts and cutoff value of 10% or 15%) retained no prognostic significance when the analyses were restricted to the subgroups of patients with a similar Hb level (< or 210 g/dL). (Fig 3) . Prognostic value of karyotype. An abnormal karyotype was also associated with a short survival (P = .003) in the 94 evaluable patients (Fig 4) . Sixty of 94 patients with evaluable karyotype died: 36 of 62 with normal karyotype and 24 of 32 with an abnormal one.
Multivariate analysis of survival: Development and validation of the scoring system (
When the survival analysis was restricted to the karyotyped patients, the scoring system remained highly significant. Cytogenetics retained prognostic value in the low-risk group (48 cases); indeed, patients with normal karyotype (33 cases) had a median survival of 112 months, whereas patients with abnormal karyotype (15 cases) had a median survival of 50 months (P = .03) (Fig 5) . Prognostic factors of death from A N U or PHT. Only two variables were found associated with a short time to death from ANLL: WBC count > 30 X 109/L ( P = .OO01) and abnormal karyotype ( P = .Ol). Eleven deaths were related to acute conversion in the subgroup of patients with evaluable karyotype: 4 cases occurred in 36 patients with a normal karyotype (11%) and 7 cases in 32 patients (25%) with an abnormal one. There was no more leukemic conversion in the splenectomized patients than in other patients: 4 of 25 splenectomized patients died from ANLL (16%).
Five variables were found associated with a short time to death from PHT: circulating blasts > 2% (P = .001), weight loss ( P = .Ol), WBC count > 3O.lO9/L ( P = .02), hepatomegaly ( P = .03) and spleen z 10 cm under the costal margin ( P = .M).
DISCUSSION
Despite of a large heterogeneity in median survival, several attempts have been made to identify clinical and labora- .'~ reticulocyte count? increased percentage of immature granulocytes, a n d or of circulating have all been found to influence survival. In the present study on 195 patients, until now the largest study in A " , the clinical and hematologic features are similar to those reported in other large series. Univariate analysis confirmed the prognostic value of most previously reported factors, especially anemia.'".'0.'4 Thrombocytopenia moderately affected survival and was not selected in multivariate analysis, probably because of a correlation with anemia, as previously demonstrated: Reticulocyte count, spleen size, and BM staging had no prognostic value. To our knowledge, this is the first time that the leukocyte count at diagnosis has been shown to be highly significant, for survival, both in univariate and in multivariate analysis; both leukopenia and high leukocytosis (>30 X 109/L) were associated with short survival. The percentage of circulating blasts was also significant, but at a lower degree, in multivariate analysis, and the percentage of immature granulocytes had only a moderate significant effect. Previous studies found prognostic value of immature granulocytes andor blasts,'.3 but comparison is difficult as their definition of WBC precursors included blasts and metamyelocytes.
Other prognostic factors have been des~ribed,'.~,'~.'~"~ m-' cluding BM biopsy, liver biopsy, ferrokinetic parameters, and, more recently, cytogenetic studies and plasma soluble interleukin-2 receptors. On BM biopsy, decreased marrow cellularity and higher degree of fibrosis (III > I1 > I) was considered of adverse prognostic value," as was pattern of BM aplasia.' Patients with mild hepatic myeloid metaplasia (HMM) survived longer than those with marked HMM in a clinicopathologic study of 22 cases.I4
Ferrokinetic studies provided sometimes conflicting results. A lower red cell volume was highly significant but not a larger plasma volume for Najean et al," and conversely for identified three prognostic subgroups by taking into account percentage of WBC precursors and Hb concentration. These scores had strong prognostic value for survival; however, their prognostic value in the present series was probably only provided by Hb level. The prognostic index presented in this report based only on two simple hematologic parameters recorded at diagnosis (Hb level and WBC count) was able to divide the patients into three groups with significantly different survival. In contrast with previous reports of prognostic systems, we could validate the present scoring system in a test population.
The difference between our results and those of other published series might be due to the following reasons: the varying criteria for diagnosis (including or not postpolycythemic MF, acute MF, or myelodysplasia with MF), the large heterogeneity of features and outcome in A " , and the large number of subjects required for the Cox proportional hazard model.
We previously reported the adverse prognostic value of abnormal karyotype: first suggested, albeit indirectly, in 1982 by Besa et all8 and recently confirmed by Reilly et al. I9 The adverse prognostic value associated with an abnormal karyotype among our low-risk patients suggested that the present scoring system might be improved by cytogenetics. The insufficient number of patients with available karyotype at the time of the analysis precluded the selection of this parameter in multivariate analysis.
Few series reported on the prognostic factors for progression to AML. High percentage of WBC precursors was associated with frequent progression to AML and short survival in twp previous studies." We found that high WBC count was associated with more frequent death from acute conversion, but high WBC precursors count was not. Patients with
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